Volume 4, Issue 8

Clinical Perspective: New AEs from Newer ART

In this issue:

While newer antiviral agents like darunavir and the integrase strand transfer inhibitor (INSTI) dolutegravir have shown great efficacy, recent postmarketing surveillance has identified important adverse effects not found in the clinical trial populations.

In this issue, Dr. Cody Chastain from the Division of Infectious Diseases at Vanderbilt University Medical Center discusses how these new findings can impact the clinical use of these new agents.

Learning objectives:

  • Describe the current evidence associating the use of dolutegravir in pregnancy with an increased rate of neural-tube defects.
  • Compare the association between darunavir and cardiovascular events with the competing benefits and possible risks of dolutegravir.

Author:

Cody Chastain, M.D.
Cody Chastain, M.D.

Assistant Professor of Medicine
Division of Infectious Diseases
Vanderbilt University Medical Center 
Nashville, TN 

Program Directors:

Allison L. Agwu, MD, ScM, FAAP, FIDSA

Associate Professor of Pediatrics and Adult Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, Maryland

Alysse G. Wurcel, MD, MS

Assistant Professor
Division of Geographic Medicine and Infectious Diseases
Tufts Medical Center
Boston, Massachusetts

Justin Alves, RN, ACRN, CARN
Infectious Disease Associates
Massachusetts General Hospital
Boston, Massachusetts

Length of activity:

0.5 hour Physicians
0.5 contact hour Nurses

Launch date: March 28, 2019
Expiration date: March 27, 2021